NTRK gene fusions in melanoma: detection, prevalence and potential therapeutic implications

Andrea Forschner,Stephan Forchhammer,Irina Bonzheim

DOI: https://doi.org/10.1111/ddg.14160

2020-07-12

Abstract:<p>Fusions involving neurotrophic tyrosine receptor kinase (NTRK) are known drivers of oncogenesis and also occur in melanoma, although very rarely. A particularly high incidence of <i>NTRK </i> gene fusions is reported in infantile fibrosarcoma (&gt; 90 %) or the secretory type of breast cancer (&gt; 90 %). Recently, larotrectinib (a tropomyosin receptor kinase [TRK] inhibitor) was approved, and we wondered whether TRK inhibitors might also be helpful for melanoma patients. We therefore screened the literature and obtained relevant results. <i>NTRK </i> fusions are relatively common in spitzoid melanoma, with a prevalence of 21–29 % compared to &lt; 1 % in cutaneous or mucosal melanoma and 2.5 % in acral melanoma. It appears that fusion proteins are mutually exclusive for most common oncogenic drivers such as BRAF or NRAS. A further indicator of an increased probability of detecting NTRK‐positive tumors could be a low mutation load. Since TRK inhibitors are already available for patients with <i>NTRK </i> fusions, the challenge will be to implement screening for <i>NTRK </i> gene fusions in clinical practice. A possible approach could be to screen <i>BRAF </i>, <i>NRAS </i> and <i>KIT </i> wild‐type melanoma patients with next‐generation sequencing as soon as they need systemic treatment or at the latest when they have no tumor control on checkpoint inhibitors.</p>

dermatology